therapeutic discovery News
-
AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration
AbCellera (Nasdaq: ABCL) today announced agreements to expand its collaboration with Gilead Sciences, Inc. (Gilead) including a multi-year, multi-target antibody discovery collaboration and access to AbCellera’s humanized mouse technology, the Trianni Mouse®. Under the financial terms of the agreements, AbCellera will receive an upfront payment and is eligible for milestone payments and ...
-
Orbit Discovery awarded Innovate UK grant to expand high throughput cell-based functional screening platform capabilities in peptide drug discovery
Oxford, United Kingdom, 13th June, 2022: Orbit Discovery Ltd., (“Orbit”) a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, has been awarded a Smart grant by Innovate UK, the UK’s innovation agency. Totalling £472,000, the grant will facilitate the ...
-
Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration
Twist Bioscience Corporation (NASDAQ:TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a broad-based research collaboration with Boehringer Ingelheim International GmbH to use Twist’s proprietary antibody libraries to discover therapeutic antibodies against multiple targets provided by Boehringer ...
-
BIO Applauds the Intent to Create a National Bioeconomy Blueprint
Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on the Obama Administration's intent to create a National Bioeconomy Blueprint: “BIO is extremely pleased that President Obama has committed to create a National Bioeconomy Blueprint to leverage the U.S. biotechnology industry to spur growth in our ...
-
Confo Therapeutics Expands Patent Estate For ConfoBody®-Based GPCR Screening Platform
Ghent, Belgium, December 15, 2021 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has extended its patent estate with four key US and EU patents granted as part of the company’s foundational “Steyaert patents”. The newly added patents (US-11,162,953, US-11,162,954, EP 3557254 and EP ...
-
NuMedii Announces Creation of World’s First Single-Cell Sequencing Atlas for Idiopathic Pulmonary Fibrosis by its Collaborators
SAN MATEO, Calif., July 9, 2020 /PRNewswire/ — NuMedii, Inc., a data-driven drug discovery company, today announced the availability of the world’s first single-cell sequencing atlas for idiopathic pulmonary fibrosis (IPF) that was the result of a strategic research collaboration including the Yale School of Medicine, Baylor College of Medicine, Brigham and Women’s Hospital, and ...
-
Amgen and Takeda join the Quantum Leap Project Led by Cqdm and Feldan Therapeutics, to Improve a Novel Intracellular Delivery Technology
CQDM is pleased to announce that following their recent enrollment in the consortium, Amgen and Takeda will be joining the syndicate of pharma companies to fund the Quantum Leap project recently launched by Feldan Therapeutics (Feldan). Amgen and Takeda will be contributing to this research project marking their first involvement in a CQDM-funded project since joining the consortium in 2018. The ...
-
HemoShear Therapeutics Advancing Novel Modulators Against Second Target for Horizon Therapeutics’ Gout Discovery Pipeline
HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates against a second target for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP). This milestone marks the fifth payment that HemoShear has earned in accordance with the Horizon exclusive ...
-
Inscopix Launches Cloud-Based Platform for Data Management and Analysis to Advance Neurotherapeutic Development
Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced that it has launched IDEAS, a cloud-based platform for enterprisesthat supports the integration, organization, management and sharing of neuroscience research, data and methods to accelerate development of the next-generation of neurotherapeutics. Today, neuroscience groups frequently use ...
-
Prellis Biologics Announces Collaboration with Sanofi
Prellis Biologics, Inc. (Prellis), a Bay Area biotherapeutics company, announced today that it has entered into a collaboration and license option agreement with Sanofi S.A. focused on the discovery of antibodies with Prellis’ first-in-class external human immune system (EXIS). The collaboration leverages Prellis’ ability to engineer fully-human lymph node organoids (LNOs™) and ...
-
Peer-Reviewed Journal Publishes Analytical Validation Results for the PrecivityAD Blood Test, Which Can Help Clinicians Detect Alzheimer’s Disease
C2N Diagnostics, which offers the PrecivityAD™ blood test that can help detect if certain markers for Alzheimer’s disease are in the brain, now has its analytical validation results available for review. The study appears in Clinica Chimica Acta, the official peer-reviewed journal of the International Federation of Clinical Chemistry and Laboratory Medicine. The article is titled ...
-
C2N Diagnostics Statement on FDA Accelerated Approval of Aducanumab forAlzheimer’s Treatment
C2N Diagnostics says the U.S. Food and Drug Administration’s (FDA) decision granting accelerated approval to aducanumab (Aduhelm) on the basis of amyloid plaque reduction for Alzheimer’s treatment represents a significant change in the ongoing fight against the horrible disease. Dr. Joel Braunstein, C2N’s CEO, said, “The accelerated approval of aducanumab will offer a ...
-
Orbit Discovery Announces $7.6 Million funding to accelerate growth in peptide discovery business
Oxford, UK – July 20, 2021 – Orbit Discovery Ltd., (“Orbit”), a privately held biopharmaceutical company focused on discovering candidate peptide therapeutics harnessing proprietary affinity and cell-based functional screening platforms, today announced that it has raised $7.6 million in funding. The financing was led by Oxford Sciences Innovation, with participation from ...
-
Rhode Island Patients Now Have Access to Breakthrough Alzheimer’s Diagnostic Blood Test
C2N Diagnostics, which offers the first widely accessible blood test to help physicians with Alzheimer’s disease diagnosis, announces that Rhode Island physicians can now use PrecivityAD™ to aid in the evaluation of their patients showing cognitive impairment. Rhode Island has joined 46 other states, the District of Columbia and Puerto Rico in granting C2N Diagnostics a CLIA ...
-
Peer-Reviewed Journal Publishes PrecivityAD™ Blood Test Research, Confirming Its Role in Assisting Clinicians in Alzheimer’s Diagnosis
A peer-reviewed journal has published the first research paper to state that the PrecivityAD™ blood test “can accurately identify brain amyloid status based on a single blood sample.” The research paper in Molecular Neurodegeneration adds that the test’s “excellent performance” for Alzheimer’s disease (AD) diagnosis allows for “improved medical ...
-
Obsidian Therapeutics & MD Anderson announce strategic collaboration to accelerate advancement of novel engineered tumor infiltrating lymphocyte therapy (cytoTIL™) for solid tumors
Obsidian Therapeutics, Inc. and The University of Texas MD Anderson Cancer Center today announced a multi-year strategic collaboration designed to expedite the research and development of novel engineered tumor infiltrating lymphocytes (TILs) for the treatment of solid tumors. The agreement pairs Obsidian and its novel cytoDRiVE™ technology platform with MD Anderson’s extensive ...
-
Two Research Studies Bolster Method That C2N’s PrecivityAD Blood Test Uses to Aid Clinicians in Alzheimer’s Disease Diagnoses
Two recent studies demonstrated that the scientific method that serves as the basis for C2N Diagnostics’ PrecivityAD™ blood test scored best compared to others assays in their respective ability to identify amyloid plaque. The C2N Diagnostics PrecivityAD™ blood test that clinicians use to aid in diagnosing Alzheimer’s disease is underpinned by the liquid ...
-
C2N Opens State-of-the-Art CLIA Lab in St. Louis as Alzheimer’s Disease Blood Diagnostic Test Bests Others in Independent Comparison Studies Published in JAMA Neurology
On World Alzheimer’s Day, Missouri leaders and economic development officials praise C2N Diagnostics for deciding to continue to grow its St. Louis-based company which is receiving international recognition for developing and accelerating novel diagnostics and therapies for Alzheimer’s disease. C2N Diagnostics has expanded its lab facilities to 13,320 square feet in the Cortex ...
-
HemoShear Therapeutics Advancing Several Novel Compounds for Horizon Therapeutics plc Gout Discovery Pipeline
HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP). This milestone marks the fourth payment that HemoShear has earned, following previous payments for the identification and ...
-
iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline
SAN DIEGO and BRYAN, Texas, Sept. 21, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announced that it closed on the acquisition of substantially all of the assets of its partner, RubrYc Therapeutics, Inc. ...
By Ibio, Inc.
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you